---  
layout: startup_page  
title: "EbsArgent"  
id: "thioredoxinsystems.com"  
permalink: "/ebsargentthioredoxinsystems.com10302024/"  
website: "http://www.thioredoxinsystems.com/"  
funding_round: "Series A"  
funding_amount: "$2.4M"  
investors: "Mikael LÃ¶nn, MD, Jens Mogensen, GU Ventures, Vasa Angels, Annexstruktur, Gobia Enterprises"  
about: "EbsArgent is a first-in-class bactericidal antibiotic for urinary tract infections (UTIs) caused by antibiotic-resistant bacteria. It uses a novel mechanism of action, combining silver ions and ebselen to disable the bacterial thioredoxin enzyme system. This approach aims to combat the growing global health threat of multidrug-resistant UTIs."  
markets: "Pharmaceuticals, Antibiotic, Healthtech"  
hq: "Solna, Stockholm, Sweden"  
founded_year: ""  
linkedin: ""  
twitter: ""  
instagram: ""  
facebook: ""  
crunchbase: ""  
pitchbook: ""  

date_display: "30-Oct-2024"  
date: "2024-10-30"

# SEO Optimization  
meta_title: "EbsArgent - Series A Funding ($2.4M)"  
meta_description: "EbsArgent, EbsArgent is a first-in-class bactericidal antibiotic for urinary tract infections (UTIs) caused by antibiotic-resistant bacteria. It uses a novel mec..."  
meta_keywords: "EbsArgent, Pharmaceuticals, Antibiotic, Healthtech, Series A funding"  
canonical_url: "https://startup.projectstartups.com/ebsargentthioredoxinsystems.com10302024/"  
---